Eli Lilly’s Mirikizumab Hits the Mark in Phase III Study, Bests Cosentyx

Eli Lilly’s experimental treatment for plaque psoriasis beat out Novartis’ vaunted drug Cosentyx in a comparison study. Mirikizumab met all primary endpoints against placebo and secondary endpoints against Cosentyx in the Phase III study, the Indianapolis-based pharma company announced.